Direct oral anticoagulants in hypercoagulable states. - Wikidata - awgldk - TriplyDB

Direct oral anticoagulants in hypercoagulable states.

Direct oral anticoagulants in hypercoagulable states.

http://www.wikidata.org/entity/Q30275936

about

Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia.Direct acting oral anticoagulants for the treatment of suspected heparin induced thrombocytopenia.

P2860

Q33440222-F3112DB4-5B06-440F-A379-81D8DB24558E Q33443237-0AC0942F-C570-4EA7-BB37-52EE25FD4B92

P2860

Direct oral anticoagulants in hypercoagulable states.

http://www.wikidata.org/entity/Q30275936

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Direct oral anticoagulants in hypercoagulable states.

@ast

Direct oral anticoagulants in hypercoagulable states.

@en

type

label

Direct oral anticoagulants in hypercoagulable states.

@ast

Direct oral anticoagulants in hypercoagulable states.

@en

prefLabel

Direct oral anticoagulants in hypercoagulable states.

@ast

Direct oral anticoagulants in hypercoagulable states.

@en

P1433

Q30275936-22CA0114-57C1-45E1-95C2-60E3C517C68B

P1476

Q30275936-97911F20-EAF7-49D9-8088-2A7CF738E6D7

P2093

Q30275936-282669B2-1045-4E99-A271-D774429510F9

Q30275936-4992FCCD-5168-44B5-8961-0E5AF6F906D0

Q30275936-94EFDB9D-9DB8-45E9-9251-DB9EC98D5FAF

Q30275936-9EA4AFC8-2FE2-4CFF-8651-8CF70F005103

Q30275936-B7F3D5A5-01CE-4B07-9CD2-25897D9291D2

P2860

Q30275936-0337DD50-AC58-4F5E-AA39-62C70D4CB02E

Q30275936-0C99B913-32A4-4F99-AC24-0BF58968BFB9

Q30275936-0E8B51BE-2BE1-4AD1-96A3-A9EFB69892C9

Q30275936-28078A04-778A-46F9-9D98-75EC24CCE25D

Q30275936-36F9F737-A71E-40B2-A263-64B9001C74BC

Q30275936-3B1B17CE-329D-452D-B254-66539A9E0F53

Q30275936-3EE8A41D-4BC0-4761-8DEA-06D0C6B37AF3

Q30275936-4C7AFFF6-E21C-4DF0-8541-3A7482FB3615

Q30275936-5CA0BF82-2C3D-4D84-A7F2-B4D438634E56

Q30275936-60711B60-83A9-4464-9E78-E80522AF34AC

P2888

Q30275936-CA564F8C-6730-4B70-AB8F-BC6D4499E2F6

P304

Q30275936-A989631D-67CA-4C3F-8283-AB4C227FBC94

P31

Q30275936-44E0F552-33E2-4FB2-9B95-BD982572297B

P356

Q30275936-C3466F96-9A7D-41E8-AF29-1CDBA4F749AC

P433

Q30275936-F5A551BD-903B-4308-B01A-CD7AD9D8A157

P478

Q30275936-0E5CABAC-4557-4F9A-8BB2-24210DA16599

P577

Q30275936-108BB264-32E9-42C6-8EC5-38523F976AC0

P698

Q30275936-E1C143AB-16A4-4276-AFD9-CFFA8D9FA5CC

P921

Q30275936-EB5862FF-84A7-4AB1-A9D6-06983B13399B

P356

S11239-016-1420-X

P1433

Journal of Thrombosis and Thrombolysis

P1476

Direct oral anticoagulants in hypercoagulable states.

@en

P2093

B Gail Macik

http://www.w3.org/2001/XMLSchema#string

Jacqueline Brown

http://www.w3.org/2001/XMLSchema#string

Melissa McShane

http://www.w3.org/2001/XMLSchema#string

Paul R Kunk

http://www.w3.org/2001/XMLSchema#string

Surabhi Palkimas

http://www.w3.org/2001/XMLSchema#string

P2860

Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

Idarucizumab for Dabigatran Reversal

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Oral rivaroxaban for symptomatic venous thromboembolism

Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.

Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Nonheparin anticoagulants for heparin-induced thrombocytopenia.

Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia.

P2888

s11239-016-1420-x

P304

79-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11239-016-1420-X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27632140

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation